Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 28;25(1):547.
doi: 10.1186/s12872-025-05013-y.

Plasma microRNA-210 is associated with VEGF-A and EphrinA3 and relates to coronary collateral circulation in patients with coronary heart disease: a cross-sectional study

Affiliations

Plasma microRNA-210 is associated with VEGF-A and EphrinA3 and relates to coronary collateral circulation in patients with coronary heart disease: a cross-sectional study

Ning Zhao et al. BMC Cardiovasc Disord. .

Abstract

Background: This study explored the interrelationships among vascular endothelial growth factor A (VEGF-A), microRNA-210 (miR-210), and EphrinA3 in the plasma of patients with coronary heart disease (CHD), and their collective influence on coronary collateral circulation (CCC) development.

Methods: We enrolled 253 patients with ≥ 90% stenosis in at least one coronary artery, stratified into good CCC (n = 99) and poor CCC (n = 154) groups according to the Rentrop grading system. Plasma concentrations of miR-210, VEGF-A, and EphrinA3 were quantified via qRT-PCR and ELISA. The associations between these biomarkers and CCC status were evaluated through correlation analysis, multivariate regression, and mediation analysis.

Results: Good CCC patients demonstrated significantly elevated plasma miR-210 (1.936 [1.099-4.118] vs. 1.272 [0.792-2.081], p < 0.001) and VEGF-A levels (3119.655 ± 850.995 vs. 2910.440 ± 713.218 pg/mL, p = 0.038), alongside reduced EphrinA3 levels (529.594 ± 143.037 vs. 584.657 ± 127.182 pg/mL, p = 0.002) compared to poor CCC patients. ROC analysis revealed AUCs of 0.656 (95% CI: 0.589-0.724) for miR-210, 0.563 (95% CI: 0.489-0.638) for VEGF-A, and 0.632 (95% CI: 0.560-0.705) for EphrinA3, which improved to 0.747, 0.696, and 0.744 respectively after adjustment for confounders. In fully adjusted multivariate models, miR-210 maintained a robust positive association with good CCC (OR: 1.558, 95% CI: 1.257-1.931, p < 0.001), with its highest tertile conferring 4.58-fold increased odds compared to the lowest tertile. Conversely, EphrinA3 exhibited a significant negative association (OR: 0.993, 95% CI: 0.990-0.997, p < 0.001), with its highest tertile linked to 79.4% reduced odds of good CCC. VEGF-A showed a modest association (OR: 1.001, p = 0.043). Notably, mediation analysis revealed that miR-210 functions as a pivotal intermediary in pathways connecting both VEGF-A and EphrinA3 to CCC formation, mediating 77.18% and 49.90% of their respective effects.

Conclusions: Plasma miR-210 levels exhibit a strong association with coronary collateral circulation development and represent a promising biomarker for CCC formation in patients with severe coronary stenosis. The influence of VEGF-A and EphrinA3 on CCC formation appears to be predominantly mediated through miR-210, highlighting its central role in coronary collateralization pathways.

Keywords: Collateral circulation; Coronary heart disease; EphrinA3; MicroRNA-210; VEGF-A.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: All experimental procedures in this study were approved by the Ethics Review Committee at the Second Norman Bethune Hospital of Jilin University. We obtained written informed consents from all patients and carried out the study following the Helsinki declaration. Clinical trial number: not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flowchart of patient enrollment. CCC, coronary collateral circulation; CABG, Coronary Artery Bypass Grafting; PCI, percutaneous coronary intervention
Fig. 2
Fig. 2
Plasma VEGF-A, miR-210 and EphrinA3 and their correlations in patients with CHD. a-c The plasma level of VEGF-A, miR-210 and EphrinA3 in CHD patients. d-f The linear correlation analysis between miR-210 and VEGF-A, miR-210 and EphrinA3, VEGF-A and EphrinA3. CHD, coronary heart disease; CCC, coronary collateral circulation
Fig. 3
Fig. 3
Plasma VEGF-A, miR-210, EphrinA3 and collateral formation. a-c The correlation analysis between VEGF-A, miR-210, EphrinA3 and Good CCC. d-f The proportion of good CCC or poor CCC from the lowest tertile to the highest tertile of VEGF-A, miR-210 and EphrinA3. g-i The nonlinear correlation analysis between miR-210, VEGF-A, EphrinA3 and Good CCC. OR, odds ratio; CCC, coronary collateral circulation
Fig. 4
Fig. 4
Receiver-operating characteristic curve analysis for identifying Good CCC. a-c ROC curves evaluating the diagnostic performance of VEGF-A, miR-210 and EphrinA3 associated with good CCC. CCC, coronary collateral circulation; ROC, receiver operating characteristic; AUC, area under the curve

Similar articles

References

    1. Chilian WM, Penn MS, Pung YF, Dong F, Mayorga M, Ohanyan V, et al. Coronary collateral growth–Back to the future. J Mol Cell Cardiol. 2012;52:905–11. - PMC - PubMed
    1. Jamaiyar A, Juguilon C, Dong F, Cumpston D, Enrick M, Chilian WM, et al. Cardioprotection during ischemia by coronary collateral growth. Am J Physiol Heart Circ Physiol. 2019;316:H1–9. - PMC - PubMed
    1. Sun XX, Li S, Fang W, Tian YQ, Shen R, Wei H, et al. Preserved myocardial viability in patients with chronic total occlusion of a single coronary artery. J Nucl Cardiol. 2021;28:2812–22. - PubMed
    1. Seiler C, Stoller M, Pitt B, Meier P. The human coronary collateral circulation: development and clinical importance. Eur Heart J. 2013;34:2674–82. - PubMed
    1. Berry C, Balachandran KP, L’Allier PL, Lespérance J, Bonan R, Oldroyd KG. Importance of collateral circulation in coronary heart disease. Eur Heart J. 2007;28:278–91. - PubMed

LinkOut - more resources